RNAZ Transcode Therapeutics (RNAZ) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001829635
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
4
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · no price filed
Transcode Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Transcode Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 16, 2022.
- The trade is 87.6% of the 56,318 shares held after it.
- 1 other insider bought within 30 days.
- 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Fitzgerald Thomas A bought about $25.2K of RNAZ on Sep 28, 2023; 1 other insider bought within 30 days and 4 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 21, 2023.
- -57.9% median (-57.2% mean) 90-day return after 6 previous buys.
- The trade is 54.4% of the 180,262 shares held after it.
- 1 other insider bought within 30 days.
- 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Dudley Robert Michael bought about $50.0K of RNAZ on Sep 28, 2023; 1 other insider bought within 30 days and 4 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jun 20, 2023.
- -57.1% median (-52.6% mean) 90-day return after 5 previous buys.
- The trade is 14.6% of the 82,262 shares held after it.
- No other insider bought within 30 days.
- 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Dudley Robert Michael bought about $31.8K of RNAZ on Jun 21, 2023; 4 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jun 9, 2023.
- -46.3% median (-46.2% mean) 90-day return after 4 previous buys.
- The trade is 9.4% of the 70,262 shares held after it.
- No other insider bought within 30 days.
- 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Dudley Robert Michael bought about $16.8K of RNAZ on Jun 20, 2023; 4 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Sep 14, 2022.
- -35.5% median (-42.1% mean) 90-day return after 3 previous buys.
- The trade is 31.1% of the 61,155 shares held after it.
- No other insider bought within 30 days.
- 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Dudley Robert Michael bought about $52.4K of RNAZ on Jun 9, 2023, the largest insider purchase at the company on our record; 4 funds added in the latest 13F quarter.9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
4 funds bought in last quarter
below 97% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.5% of the float short (float per yahoo 2026-10-27) · 1.4 days to cover · settled 2026-10-15
below 82% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RNAZ
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-87.0%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RNAZ: institutional holders (13F)
13F holdings, latest reported quarter
19,639 sh
$122.0K
6,545 sh
$40.6K
2,982 sh
$18.5K
2,888 sh
$17.9K
1,535 sh
$9.5K
Congress trades in RNAZ
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RNAZ planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
RNAZ mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$43.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$40.6K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$6.1K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$2.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Early Phase 1
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 4 funds added last quarter. Each figure is a federal filing, dated the day it went public.
RNAZ financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM RNAZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM RNAZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$22.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RNAZ
| FY Dec 2025 | -$19.5M |
| FY Dec 2024 | -$13.4M |
| FY Dec 2023 | -$18.1M |
| FY Dec 2022 | -$15.9M |
| FY Dec 2021 | -$5.5M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$3.1M |
| Sep 2024 | -$3.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity RNAZ
| FY Dec 2025 | 0.21x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 1.30x |
| FY Dec 2022 | 0.66x |
| FY Dec 2021 | 0.10x |
| Jun 2026 | n/a |
| Mar 2026 | 1.70x |
| Dec 2025 | 0.21x |
| Sep 2025 | 1.49x |
| Jun 2025 | 0.35x |
| Mar 2025 | 0.21x |
| Dec 2024 | n/a |
| Sep 2024 | 1.29x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-10.63x
TTM operating cash flow over long-term debt only, 2021-07-13 (60 months older than the period end)
Cash flow to debt RNAZ
| FY Dec 2025 | -9.18x |
| FY Dec 2024 | -6.27x |
| FY Dec 2023 | -8.50x |
| FY Dec 2022 | -7.41x |
| FY Dec 2021 | -2.48x |
| Jun 2026 | -10.63x |
| Mar 2026 | -10.06x |
| Dec 2025 | -9.18x |
| Sep 2025 | -6.83x |
| Jun 2025 | -6.75x |
| Mar 2025 | -5.88x |
| Dec 2024 | -6.27x |
| Sep 2024 | -7.46x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity RNAZ
| FY Dec 2025 | -833.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -759.9% |
| FY Dec 2022 | -148.6% |
| FY Dec 2021 | -80.5% |
| Jun 2026 | n/a |
| Mar 2026 | -699.2% |
| Dec 2025 | -833.5% |
| Sep 2025 | -1,763% |
| Jun 2025 | -658.6% |
| Mar 2025 | -343.0% |
| Dec 2024 | n/a |
| Sep 2024 | -490.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-53.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RNAZ
| FY Dec 2025 | -40.9% |
| FY Dec 2024 | -268.8% |
| FY Dec 2023 | -290.7% |
| FY Dec 2022 | -115.1% |
| FY Dec 2021 | -57.0% |
| Jun 2026 | -53.8% |
| Mar 2026 | -47.4% |
| Dec 2025 | -40.9% |
| Sep 2025 | -592.3% |
| Jun 2025 | -375.8% |
| Mar 2025 | -249.1% |
| Dec 2024 | -268.8% |
| Sep 2024 | -210.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital RNAZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-59.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RNAZ
| FY Dec 2025 | -34.2% |
| FY Dec 2024 | -505.0% |
| FY Dec 2023 | -789.4% |
| FY Dec 2022 | -157.6% |
| FY Dec 2021 | -58.4% |
| Jun 2026 | -59.3% |
| Mar 2026 | -52.4% |
| Dec 2025 | -34.2% |
| Sep 2025 | -871.7% |
| Jun 2025 | -365.2% |
| Mar 2025 | -203.6% |
| Dec 2024 | -505.0% |
| Sep 2024 | -466.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RNAZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$22.6M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term debt only, 2021-07-13 (60 months older than the period end), minus cash 2026-06-30
Enterprise value RNAZ
| FY Dec 2025 | -$9.4M |
| FY Dec 2024 | $1.6B |
| FY Dec 2023 | $122.6B |
| FY Dec 2022 | $6.5T |
| FY Dec 2021 | n/a |
| Jun 2026 | -$355.9K |
| Mar 2026 | -$2.8M |
| Dec 2025 | -$9.4M |
| Sep 2025 | $8.3M |
| Jun 2025 | $176.8M |
| Mar 2025 | $229.9M |
| Dec 2024 | $1.6B |
| Sep 2024 | $9.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-78.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield RNAZ
| FY Dec 2025 | -312.0% |
| FY Dec 2024 | -0.8% |
| FY Dec 2023 | -0.0% |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | n/a |
| Jun 2026 | -383.4% |
| Mar 2026 | -271.3% |
| Dec 2025 | -312.0% |
| Sep 2025 | -162.3% |
| Jun 2025 | -7.9% |
| Mar 2025 | -5.2% |
| Dec 2024 | -0.8% |
| Sep 2024 | -0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RNAZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$28.0M | -$15.7M | -$19.4M | -$18.6M |
| Net income | -$34.7M | -$16.8M | -$18.5M | -$17.6M |
| EPS (diluted) | -52.59 | -1,336.63 | -3,419.01 | -1,082.79 |
| Operating cash flow | -$19.5M | -$13.3M | -$18.1M | -$15.8M |
| Cash | $17.8M | $5.8M | $2.8M | $5.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
RNAZ Stock Sonar score 4/7 axes
Find similar shapesCompareRNAZ ranks highest on risk and compliance (71st percentile) and profitability (42nd), and lowest on institutional and government (3rd), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
